Trials / Terminated
TerminatedNCT00366327
Study Evaluating Bifeprunox in Patients With Schizophrenia.
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 66 Years
- Healthy volunteers
- Not accepted
Summary
An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bifeprunox | Flex dose (20 or 30 mg)tablet, QD for 1 year |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2006-08-21
- Last updated
- 2013-02-11
Locations
82 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00366327. Inclusion in this directory is not an endorsement.